Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat female hormone-dependent cancers. Context’s lead program is onapristone extended release (ONA-XR), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) breast, endometrial, and ovarian cancers.